Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Semin Immunol ; 39: 14-21, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29801750

RESUMEN

After decades of slow progress, the last years have seen a rapid acceleration of the development of adjuvanted vaccines which have lately been approved for human use. These adjuvants consist of different components, e.g. aluminium salts, emulsions such as MF59 and AS03, Toll-like receptor (TLR) agonists (CpG ormonophosphoryl lipid A (MPL) adsorbed on aluminium salts as in AS04) or combination of immunopotentiators (QS-21 and MPL in AS01). Despite their distinctive features, most of these adjuvants share some key characteristics. For example, they induce early activation (although at different levels) of innate immunity which then translates into higher antibody and cellular responses to the vaccine antigens. In addition, most of these adjuvants (e.g. MF59, AS03, AS04) clearly induce a wider breadth of adaptive responses able to confer protection against, for example, heterovariants of the influenza viruses (MF59, AS03) or against human papillomavirus strains not contained in the vaccine (AS04). Finally, the use of some of these adjuvants has contributed to significantly enhance the immune response and the efficacy and effectiveness of vaccines in the elderly who experience a waning of the immune responsiveness to infection and vaccination, as shown for MF59- or AS03-adjuvanted influenza vaccines and AS01-adjuvanted herpes zoster vaccine. These results, together with the track record of acceptable safety profiles of the adjuvanted vaccines, pave the way for the development of novel vaccines at the extremes of age and against infections with a high toll of morbidity and mortality. Here, we review the mechanisms associated with the performance of those adjuvanted vaccines in animal models and in humans through recent advances in systems vaccinology and biomarker discovery. We also provide some perspectives on remaining knowledge gaps but also on opportunities that could accelerate the development of new vaccines.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Herpes Zóster/prevención & control , Inmunidad Celular/efectos de los fármacos , Inmunogenicidad Vacunal , Gripe Humana/prevención & control , Infecciones por Papillomavirus/prevención & control , Adyuvantes Inmunológicos/química , Anciano , Animales , Combinación de Medicamentos , Herpes Zóster/inmunología , Herpes Zóster/virología , Humanos , Inmunidad Humoral/efectos de los fármacos , Gripe Humana/inmunología , Gripe Humana/virología , Liposomas/administración & dosificación , Liposomas/química , Liposomas/inmunología , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/virología , Polisorbatos/química , Polisorbatos/farmacología , Escualeno/química , Escualeno/farmacología , Células TH1/efectos de los fármacos , Células TH1/inmunología , Células TH1/microbiología , Células Th2/efectos de los fármacos , Células Th2/inmunología , Células Th2/microbiología , Vacunas Virales/administración & dosificación , Vacunas Virales/química , Vacunas Virales/inmunología , alfa-Tocoferol/química , alfa-Tocoferol/farmacología
2.
J Infect Dis ; 211(1): 156-65, 2015 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-25139019

RESUMEN

BACKGROUND: A predominantly T-helper type 2 (Th2) immune response is critical in the prognosis of pulmonary Pseudomonas aeruginosa infection. But the mucosal and systemic immune responses can be influenced by the intestinal microbiota. METHODS: We assessed the effect of microbiota compositional changes induced by a diet enriched in 5% acidic oligosaccharides derived from pectin (pAOS) on the immune response and outcome of chronic pulmonary P. aeruginosa infection in mice. RESULTS: pAOS promoted Th1 polarization by increasing interferon γ release, upregulating t-bet gene expression, decreasing interleukin 4 secretion, and downregulating gata3 gene expression. pAOS also sustained the release of keratinocyte chemoattractant, recruited polynuclear leukocytes and macrophages, stimulated M1 macrophage activation and interleukin 10 release, and decreased tumor necrosis factor α release in the lung. These effects led to increased bacterial clearance after the first and second P. aeruginosa infections. pAOS modified the intestinal microbiota by stimulating the growth of species involved in immunity development, such as Bifidobacterium species, Sutturella wadsworthia, and Clostridium cluster XIVa organisms, and at the same time increased the production of butyrate and propionate. CONCLUSION: These results suggest that pAOS may have beneficial effects by limiting the number and severity of pulmonary exacerbations in patients chronically infected with P. aeruginosa, such as individuals with cystic fibrosis.


Asunto(s)
Intestinos/efectos de los fármacos , Intestinos/microbiología , Enfermedades Pulmonares/tratamiento farmacológico , Microbiota/efectos de los fármacos , Oligosacáridos/farmacología , Pectinas/química , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Animales , Factores Quimiotácticos/inmunología , Factor de Transcripción GATA3/inmunología , Interferón gamma/inmunología , Interleucina-10/inmunología , Interleucina-4/inmunología , Intestinos/inmunología , Queratinocitos/inmunología , Queratinocitos/microbiología , Leucocitos/inmunología , Leucocitos/microbiología , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/microbiología , Macrófagos/inmunología , Macrófagos/microbiología , Masculino , Ratones , Ratones Endogámicos BALB C , Microbiota/inmunología , Infecciones por Pseudomonas/inmunología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/crecimiento & desarrollo , Proteínas de Dominio T Box/inmunología , Células TH1/inmunología , Células TH1/microbiología , Factor de Necrosis Tumoral alfa/inmunología
3.
J Microencapsul ; 31(6): 560-6, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24697189

RESUMEN

Vaccination using proteins and peptides is currently gaining importance. One of the major drawbacks of this approach is the lack of an efficient immune response when the antigens are administered without adjuvants. In this study, we have taken the advantage of a combined adjuvant system in order to improve the immunogenicity of the SPf66 malarial antigen. For that purpose, we have combined poly (lactic-co-glycolic) acid microspheres, alginate, and polyinosinic polycytidilic acid. Our results show that microspheres can enhance the IgG production obtained with Freund's complete adjuvant. We have attributed this improvement to the presence of polyinosinic polycytidilic acid, since formulations comprising this adjuvant overcame the immune response from the others. In addition, our microspheres produced both IgG1 and IgG2a, leading to mixed Th1/Th2 activation, optimal for malaria vaccination. In conclusion, we have designed a preliminary formulation with a high potential for the treatment of malaria.


Asunto(s)
Alginatos , Inductores de Interferón , Ácido Láctico , Vacunas contra la Malaria , Microesferas , Poli I-C , Ácido Poliglicólico , Alginatos/química , Alginatos/farmacología , Animales , Anticuerpos Antiprotozoarios/sangre , Anticuerpos Antiprotozoarios/inmunología , Femenino , Ácido Glucurónico/química , Ácido Glucurónico/farmacología , Ácidos Hexurónicos/química , Ácidos Hexurónicos/farmacología , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Inductores de Interferón/química , Inductores de Interferón/farmacología , Ácido Láctico/química , Ácido Láctico/farmacología , Malaria/sangre , Malaria/inmunología , Malaria/prevención & control , Vacunas contra la Malaria/química , Vacunas contra la Malaria/farmacología , Ratones , Ratones Endogámicos BALB C , Poli I-C/química , Poli I-C/farmacología , Ácido Poliglicólico/química , Ácido Poliglicólico/farmacología , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Células TH1/inmunología , Células TH1/microbiología , Células Th2/inmunología , Células Th2/metabolismo
4.
J Nutr ; 136(5): 1365-70, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16614431

RESUMEN

Vitamin A supplementation has consistently reduced infant mortality and the severity of pathogen-induced diarrhea. The mechanism by which vitamin A modulates the mucosal immune response to produce these effects remains poorly defined. To address this issue, stools collected during the summer months from 127 Mexican children 5-15 mo old enrolled in a larger, randomized, double-blind, placebo-controlled, vitamin A supplementation trial were screened for interleukin (IL)-4, IL-6, interferon-gamma (IFN-gamma), and gastrointestinal pathogens. Fecal cytokine values were categorized into 3 levels (undetectable, or =median). Multinomial regression models were used to determine the probability that vitamin A-supplemented children had higher categorical values of a cytokine than children in the placebo group. Differences in categorical values were also analyzed after stratification by gastrointestinal pathogen infections and diarrheal symptoms. Overall, fecal cytokine categorical levels did not differ between children randomized to the 2 arms. Vitamin A-supplemented children infected with enteropathogenic E. coli (EPEC) had reduced IL-4 and IFN-gamma levels [odds ratio (OR) = 0.3, 95% CI 0.13-0.67 and OR = 0.34, 95% CI 0.14-0.83, respectively] compared with children in the placebo group. Vitamin A-supplemented children had increased IL-4 levels when infected with A. lumbricoides (OR = 12.06, 95% CI 0.95-153.85). In contrast, IL-4 levels increased (OR = 2.14, 95% CI 0.94-4.87) and IFN-gamma levels decreased (OR = 0.51, 95% CI 0.26-0.99) among vitamin A-supplemented children with diarrhea compared with children in the placebo group. These findings suggest that the regulation of the mucosal immune response by vitamin A may depend on the type of enteric pathogen infecting the child and the presence of clinical symptoms.


Asunto(s)
Diarrea/inmunología , Suplementos Dietéticos , Inmunidad Mucosa/efectos de los fármacos , Vitamina A/farmacología , Animales , Ascariasis/inmunología , Ascaris/aislamiento & purificación , Estatura , Peso Corporal , Control de Enfermedades Transmisibles , Diarrea/parasitología , Heces/parasitología , Femenino , Humanos , Lactante , Masculino , México , Factores Socioeconómicos , Células TH1/microbiología , Células Th2/inmunología
5.
J Immunol ; 168(8): 3950-7, 2002 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-11937551

RESUMEN

Lactoferrin (Lf) is an iron-binding protein of external secretions and neutrophil secondary granules with antimicrobial and immunomodulatory activities. To further define these properties of Lf, we have investigated the response to Staphylococcus aureus infection in transgenic mice carrying a functional human Lf gene. The transgenic mice cleared bacteria significantly better than congenic littermates, associated with a trend to reduced incidence of arthritis, septicemia, and mortality. We identified two pathways by which S. aureus clearance was enhanced. First, human Lf directly inhibited the growth of S. aureus LS-1 in vitro. Second, S. aureus-infected transgenic mice exhibited enhanced Th1 immune polarization. Thus, spleen cells from infected transgenic mice produced higher levels of TNF-alpha and IFN-gamma and less IL-5 and IL-10 upon stimulation ex vivo with the exotoxin toxic shock syndrome toxin-1 compared with congenic controls. To confirm that these effects of Lf transgene expression could occur in the absence of live bacterial infection, we also showed that Lf-transgenic DBA/1 mice exhibited enhanced severity of collagen-induced arthritis, an established model of Th1-induced articular inflammation. Higher levels of stainable iron in the spleens of transgenic mice correlated with human Lf distribution, but all other parameters of iron metabolism did not differ between transgenic mice and wild-type littermates. These results demonstrate that human Lf can mediate both antimicrobial and immunomodulatory activities with downstream effects on the outcome of immune pathology in infectious and inflammatory disease.


Asunto(s)
Adyuvantes Inmunológicos/genética , Lactoferrina/genética , Ratones Transgénicos/inmunología , Infecciones Estafilocócicas/genética , Infecciones Estafilocócicas/inmunología , Células TH1/inmunología , Células TH1/microbiología , Adyuvantes Inmunológicos/biosíntesis , Adyuvantes Inmunológicos/fisiología , Adyuvantes Inmunológicos/uso terapéutico , Animales , Artritis Experimental/genética , Artritis Experimental/inmunología , Artritis Experimental/microbiología , Artritis Infecciosa/genética , Artritis Infecciosa/inmunología , Artritis Infecciosa/microbiología , Citocinas/biosíntesis , Citocinas/sangre , Humanos , Hierro/metabolismo , Lactoferrina/biosíntesis , Lactoferrina/fisiología , Lactoferrina/uso terapéutico , Hígado/metabolismo , Activación de Linfocitos/genética , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Ratones Endogámicos DBA , Bazo/citología , Bazo/inmunología , Bazo/metabolismo , Bazo/patología , Infecciones Estafilocócicas/metabolismo , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/crecimiento & desarrollo , Staphylococcus aureus/inmunología , Células TH1/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA